Altre lingue Attana AB

Azioni

ATANA

SE0010547273

Prezzo di chiusura NORDIC GROWTH MARKET Altri mercati azionari 00:00:00 25/04/2024			Variaz. 5gg	Var. 1 gen.
0,075 ^SEK	-8,54%		+8,70%	-24,24%

25/04	Attana AB entra nel terzo anno di un contratto di servizio e assistenza quinquennale con un istituto sanitario leader negli Stati Uniti	CI
22/02	Attana AB riporta i risultati degli utili per il quarto trimestre e l'intero anno terminato il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Attana enters the third year of a five-year service and support contract with a leading health institute in the US	25/04
Attana AB Enters Third Year of A Five-Year Service and Support Contract with A Leading Health Institute in the US	25/04
New paper using Attana tecnology to understand how viruses enter human cells	01/04
One of US leading health institutes has placed an order for an upgrade of an existing instrument, valued at $150k	05/03
Attana AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	22/02
New paper using Attana Technology to study structures on surface in Ion Liquids demonstrating the effect of surface charges on interaction properties.	13/02
New publication using Attana technology towards environmentally friendly and financially viable methods to create functional materials	23/01
New article using Attana's technology from National University of Singapore: Immunity differences in vaccinated individuals according to age, gender, lifestyle and other diseases	20/12
Biosensors to characterize immune response to bacterial diseases	18/12
Attana and Linnaeus University have published the first part of the science behind immunity profiles	05/12
Attana Lands Order for Kinetic Interaction Analysis of Tissue in US	04/12
Breakthrough order with new customer in the USA	04/12
Attana AB Receives Breakthrough Order with New Customer in the USA	04/12
Strengthened collaboration with European biotech customer who extends their service and support agreement for another 12 months.	23/11
Customer Develops Therapeutic Antibodies Against Cancer and Uses Attana's Cell-Based Technology	23/11
A new publication using Attana Technology from National University of Singapore examining the neutralization capacity of human IgG antibodies agsinst different mutations of the SARS-CoV-2	20/11
Robust QCM-Based Sensing and Assay Formats in Commercialized Systems	15/11
Attana AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	26/10/23
Dear shareholders and valuable followers,	04/10/23
New publication that shows the strength of Attana's offering in diagnostics, here applied in veterinary medicine.	26/09/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Attana AB

Azioni

ATANA

SE0010547273

Altre lingue

Filtri